Healthcare provider profile · identity verified

George T Crabb, DO

Internal Medicine · NAPLES, FL · NPI 1033100342

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	375	145
Amlodipine Besylate	Amlodipine Besylate	218	90
Lisinopril	Lisinopril	204	81
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	165	35
Levothyroxine Sodium	Levothyroxine Sodium	165	60
Metformin Hcl	Metformin Hcl	155	58
Losartan Potassium	Losartan Potassium	135	53
Omeprazole	Omeprazole	127	54
Atenolol	Atenolol	126	48
Albuterol Sulfate Hfa	Albuterol Sulfate	123	65
Potassium Chloride	Potassium Chloride	112	46
Rosuvastatin Calcium	Rosuvastatin Calcium	112	50
Gabapentin	Gabapentin	105	42
Pantoprazole Sodium	Pantoprazole Sodium	105	38
Glipizide	Glipizide	103	42
Metformin Hcl Er	Metformin Hcl	89	36
Hydrochlorothiazide	Hydrochlorothiazide	81	34
Terazosin Hcl	Terazosin Hcl	79	30
Simvastatin	Simvastatin	76	35
Furosemide	Furosemide	57	25
Trazodone Hcl	Trazodone Hcl	55	21
Allopurinol	Allopurinol	49	20
Alendronate Sodium	Alendronate Sodium	45	16
Metoprolol Tartrate	Metoprolol Tartrate	44	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	13
Ozempic	Semaglutide	44	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	43	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	43	19
Meloxicam	Meloxicam	41	17
Montelukast Sodium	Montelukast Sodium	41	18
Fluticasone Propionate	Fluticasone Propionate	40	13
Prednisone	Prednisone	40	34
Pradaxa	Dabigatran Etexilate Mesylate	39	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	12
Triamcinolone Acetonide	Triamcinolone Acetonide	34	19
Bisoprolol Fumarate	Bisoprolol Fumarate	33	13
Ibuprofen	Ibuprofen	33	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	12
Wixela Inhub	Fluticasone Propion/Salmeterol	33	13
Tramadol Hcl	Tramadol Hcl	32	suppressed
Humulin N	Insulin Nph Human Isophane	30	suppressed
Spiriva Respimat	Tiotropium Bromide	30	suppressed
Finasteride	Finasteride	29	suppressed
Jardiance	Empagliflozin	29	11
Metoprolol Succinate	Metoprolol Succinate	29	suppressed
Alvesco	Ciclesonide	28	13
Famotidine	Famotidine	28	13
Clopidogrel	Clopidogrel Bisulfate	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	11
Eliquis	Apixaban	24	suppressed
Levofloxacin	Levofloxacin	24	20
Lactulose	Lactulose	21	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Hydrocortisone	Hydrocortisone	19	11
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Cephalexin	Cephalexin	17	11
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Lidocaine	Lidocaine	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Valsartan	Valsartan	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Lorazepam	Lorazepam	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	12	12
Azelastine Hcl	Azelastine Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Nystatin	Nystatin	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Baclofen	Baclofen	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error